Elixiron Immunotherapeutics (Cayman) Limited (7871)
Market Closed
13 Aug, 05:30
TWSE TWSE Primary NT$
94. 80
+0.9
+0.9585%
NT$
- Market Cap
- P/E Ratio
- Div Yield
1.74M Volume
- Eps
NT$ 93.9
Previous Close Want to track 7871 and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Elixiron Immunotherapeutics (Cayman) Limited (7871) Statistics
Valuation metrics
Market Cap -
Enterprise value 10.16B
Trailing P/E (ttm) -
Forward P/E -
PEG ratio -
Price/Sales (ttm) -
Price/Book (mrq) 13.23
Enterprise Value/Revenue 202.02
Enterprise Value/EBITDA -53.02
Overview
Shares outstanding -
Float 90.43M
Shares short -
% Held by insiders -
% Held by institutions -
Average volume (10 days) 796.87K
Average volume (90 days) 1.15M
Price summary
52-Week low 37.55
52-Week high 105
Beta -
50-Day moving average 76.23
200-Day moving average 70.33
Financials
Fiscal year
Fiscal year ends 31 Dec 2025
Most recent quarter (mrq) 31 Dec 2025
Profitability
Profit margin -
Operating margin -2.39%
Operational effectiveness
Return on assets -0.23%
Return on equity -
Income Statement
Revenue (ttm) 50.29M
Revenue per share (ttm) 0.64
Quarterly revenue growth (yoy) 61.35%
Gross profit (ttm) 49.98M
EBITDA -191.61M
Net income to common (ttm) -1.11B
Diluted EPS (ttm) -
Quarterly earnings growth (yoy) -
Balance Sheet
Total cash (mrq) 863.36M
Total cash per share (mrq) 6.43
Total debt (mrq) 24.94M
Total Debt/Equity (mrq) 3.01
Current ratio (mrq) 10.03%
Book value per share (mrq) 6.17
Cash Flow
Cash flow statement -131.97M
Levered free cash flow (LFCF) -84.8M
